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tory syncytial virus (RSV) lower respiratory 
tract infection (LRI) in patients with age 
0–2 months, 3–5 months and 6–8 months is 
0, 50 and 198, respectively, per 1000 child-
years.1 These numbers are in-line with the 
accumulated cohort data from the Utrecht 
RSV Research group.2 These studies allow 
for the conclusion that RSV bronchiolitis is 
relatively rare during the first months of life, 
but when it occurs, the course of disease is 
severe. It seems obvious that both incidence 
and severity of RSV LRI during infancy 
determine the burden of disease. Thus, we 
agree with Cooper and colleagues that the 
burden of RSV LRI in children 3–6 months 
is quite substantial despite the consistent 
observation that incidence is lower than in 
children 7–12 months.
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done in other developing countries, hand 
in hand with vaccine development efforts, 
with the goal of early vaccine introduction 
where the burden of illness is greatest.
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Reply:
We thank Cooper and colleagues for their comments on our article and that 
by Simões and co-workers.1,2 They bring up 
the highly interesting question what inci-
dence should be considered substantial. 
Simões found that the incidence of respira-
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The Need to 
Capitalize on New 
Recommendations
Stimulating Tuberculosis 
Diagnostic Research in 
Children
 To the Editors:
This year, the focus for World Tuberculo-sis (TB) day was children, a neglected 
area despite the fact that TB causes an esti-
mated 70,000 childhood deaths each year.1 
The starting point for this neglect is the 
lack of appropriate diagnostic tests for TB 
in children, which means that the disease 
is underdetected and underreported. Using 
a conservative estimate of children repre-
senting 5% of the adult prevalence of 9.97 
million, then the gap between the numbers 
The authors have no funding or conflicts of interest 
to disclose.
expected and cases actually reported, shows 
a potential 341,365 cases not diagnosed or 
reported in children during 2010.2
Existing diagnostic tests are not 
adapted for children, and thus it is difficult 
to confirm active TB. Sputum-based tests, 
the usual approach to confirm active TB in 
adults, have far less yield in children who 
often struggle to produce sputum. There is 
a desperate need for rapid, accurate, non-
sputum-based diagnostic tests for children, 
suitable for implementation in resource-
limited settings. Research into diagnostic 
tests for children has been hampered by the 
lack of a unanimously recognized standard 
for pediatric TB diagnosis. This has con-
tributed to a reluctance to enroll children in 
studies involving new diagnostic technolo-
gies. Of the promising new methods: Gene 
Xpert Mtb/Rif, microscopic observation 
drug-susceptibility assay, nitrate reductase 
assay, colorimetric redox indicator assay, 
line-probe assay and loop-mediated isother-
mal amplification, studies are either lim-
ited or completely lacking in children. The 
comparison of existing pediatric diagnostic 
studies is extremely difficult, with little or 
no standardization of the definitions.3
In March 2012, a consensus state-
ment on critical aspects of TB diagnostic 
research in children was published. This 
represents a significant advance toward 
improved diagnostics for pediatric TB. The 
expert panel consensus was reached in a 
National Institutes of Health–sponsored 
meeting of pediatric TB experts in June 
2011 “Critical Issues in Pediatric Tubercu-
losis Diagnostics Research in HIV-Infected 
and Uninfected Children.” The meeting had 
2 key outcomes: consensus on clinical case 
definitions of intrathoracic TB in children, 
and methodologic approaches to apply for 
the evaluation of TB diagnostics in chil-
dren.4,5 The consensus agreed on 5 clinical 
case definitions with further details regard-
ing microbiologic confirmation, clinical 
signs and symptoms, interpretation of chest 
radiographs, TB exposure and response to 
treatment to support these case definitions.
Research into TB diagnostics is 
grossly underfunded with the only 13% 
of the $340 million recommended by the 
Global plan raised in 2011 and only 8% of 
total research and development investment 
committed to diagnostics.6 This funding 
gap needs to be addressed, and it is essen-
tial that this particularly challenging and 
neglected area of TB diagnostics should not 
suffer from cutbacks in this period of finan-
cial austerity. Dedicated funding streams 
for research into diagnostics in children are 
needed, and children should be routinely 
included in research.
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These new consensus statements 
mean that there is no longer an excuse 
to continue to exclude children from TB 
 diagnostic research. It is vital that these 
recommendations are endorsed by funding 
agencies, research organizations and diag-
nostic developers.
Grania Brigden, MB ChB, MRCP
Médecins Sans Frontières – 
Access Campaign  
Geneva, Switzerland
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Does Solely Clinical 
Diagnostics Lead to 
Overdiagnoses and 
Overtreatments?
Pneumonia in Children
 To the Editors:
British Thoracic Society (BTS) and Infec-tious Disease Society of America have 
recently published their evidence-based 
guidelines for the management of pediatric 
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community-acquired pneumonia (CAP).1,2 
In this journal, the members of CAP Paedi-
atric Research Initiative of European Society 
for Paediatric Infectious Diseases published 
a review on antibiotic therapy for pediat-
ric CAP.3 The authors concluded that their 
review is a discussion paper with an aim of 
stimulating further debate and research.3
Both BTS and Infectious Disease 
Society of America guidelines recommend 
that the diagnosis of CAP in children be 
based solely on clinical criteria. Chest 
radiographs are indicated only in severe 
cases treated in hospital or when complica-
tions are suspected.1,2 According to the BTS 
guidelines, bacterial pneumonia should be 
considered in children when there is per-
sistent or repetitive fever >38.5°C accom-
panied with chest retractions and a raised 
respiratory rate.1 Most children with CAP 
should be treated with antibiotics, with 
only a few exceptions, such as <24 months 
(BTS)1 or <6 years (Infectious Disease 
Society of America)2 old children with mild 
symptoms.1,2 The guidelines remind that 
pneumonia is uncommon in wheezing chil-
dren though other presentations are similar, 
such as fever, chest retractions and raised 
respiratory rate.
Esposito et al3 conclude in their 
review that there is no standard for estab-
lishing the diagnosis of CAP, but chest 
radiograph still is the best available mean 
of diagnosing pneumonia. The presence 
of alveolar infiltration is, more often than 
interstitial infiltration, associated with bac-
terial pneumonia. Despite this, the authors 
do not suggest confirming presumed pneu-
monia cases by radiology. Children with 
mild CAP for whom all of the available epi-
demiologic, clinical, laboratory and radio-
logic data clearly suggest a viral infection 
can be treated with symptomatic therapy 
alone.3 A history of conjugate pneumococ-
cal vaccination gives greater confidence in 
the decision to withhold antibiotics.1
An alternative way is to diagnose 
CAP by chest radiograph and treat only 
radiologically confirmed CAP cases.4 The 
goal is to treat only “true pneumonia” cases 
with antibiotics. A short, 12–48 hours inpa-
tient treatment using intravenous admin-
istration ensures rapid effect and close 
monitoring, and even enables the use of 
narrow-spectrum antibiotics such as penicil-
lin G. According to the guidelines, improve-
ment should begin within 48 hours after the 
start of antibiotics.1 In both developing and 
developed countries, pneumonia cannot be 
confirmed by radiology in >80% of children 
with a clinical suspicion of pneumonia,4 
and these children are treated unnecessarily 
with antibiotics. On the other hand, taking 
more radiographs may lead to more findings 
which are mistakenly considered as pneu-
monia. To avoid overdiagnostics, only clear 
pulmonary consolidations should be inter-
preted as pneumonic changes.4
Physicians prescribe antibiotics for 
children with respiratory infection for many 
reasons which are not medically justified, 
because of diagnostic uncertainty, parental 
wish and fear of complications. Diagnos-
ing pediatric CAP by clinical symptoms and 
signs alone probably increases the use of 
unnecessary antibiotics. Focusing antibiotic 
treatment to those who really benefit from 
the treatment and using narrow-spectrum 
antibiotics prevent emerging antibiotic 
resistance in the population. If the radiologic 
or clinical findings are mild or nonspecific, 
antibiotic therapy is usually not needed.
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